Presently the company works on a research program called DiagAlz, in which two tests for Alzheimer’s disease detection are under development. These tests are carried out on blood samples and can be performed even before the first clinical symptoms appearance.
The company will commercialize the first tests during 2009, being one of the first world-leading companies with blood diagnostic tests for Alzheimer’s disease. We will also offer pre-clinical evaluation of disease modifying drugs to companies involved in drug development.

Alzheimer’s disease is a heavy social and economical burden for developed countries and will soon become as problematic for rapidly growing economies. Since this disease is related to aging its occurrence increases with life expectancy. The initial phase of the disease is generally slow leading to progressive cognitive decline. Using biological tests for diagnosis before pathological clinical symptoms would support an early treatment, which consequently would be more efficient. This represents one of the most promising tracks against Alzheimer’s disease.
Xavier Regnaut (Agro Engineer, Master of genetics, EMBA HEC) is the IHD President. Before founding IHD, he managed several innovative companies in the field of biotechnologies and food industries. He has also been director of the “Réseau Entreprendre” and he is experienced in setting up and financing companies, as well as in international trading.
Dr. Jean de Barry (PhD, Chemistry Engineer) is an INSERM senior researcher. He works at the Institute of Cellular and Integrative Neurosciences (INCI) (UMR7168 CNRS - Louis Pasteur University of Strasbourg). Diagnostic methods developed by our company are issued from his research. Dr de Barry is scientific advisor for IHD. He has published more than 50 scientific papers.
Dr. François Sellal (MD, PH) is both neurologist and clinician specialist for Alzheimer’s disease. He is head of the “Consultation Mémoire, de Ressource et de Recherche (CM2R)” for the Alsace region. CM2R is a specialized center undertaking Alzheimer’s patients. He is also head of the neurological department from the hospital of Colmar. He supervises the clinical research. He has published more than 70 scientific papers.